The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.
Aignostics
Series B in 2024
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
CustomSurg
Seed Round in 2024
Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Kranus Health
Series A in 2023
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
InContAlert
Pre Seed Round in 2023
inContAlert is a deep tech start-up disrupting the field of incontinence. The technology of inContAlert helps people with bladder dysfunction to monitor the filling level of their urinary bladder. -- no more unnecessary catheters. no more needless emptying through nurses. no more diapers -- inContAlert, therefore, developed an mHealth device, which collects and analyzes data with the help of deep learning algorithms. The information is then displayed on an app and sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine or the harmful distension of the bladder. With the help of inContAlert, incontinence patients can go back to normal and live a carefree life.
Hema.to
Seed Round in 2023
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.
Phialogics
Pre Seed Round in 2023
Phialogics is a preclinical biotechnology company that specializes in developing advanced biologics aimed at modulating the immune response in cases of acute and chronic inflammation. The firm focuses on creating cell therapies for the treatment of autoimmune diseases by employing protein engineering techniques to design cell-type-specific immune checkpoint activators. These innovations enable the production of signaling agonists that effectively influence the activity of immune cells, thereby assisting healthcare professionals in preventing multi-organ failure associated with autoimmune conditions.
Mosanna Therapeutics
Seed Round in 2023
Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach.
Mbiomics
Series A in 2023
Mbiomics is a biotechnology company focused on microbiome research, diagnostics, and therapeutics. It has developed a high-throughput, low-cost platform that allows for dynamic and real-time analysis and quantification of the human gut microbiome. By providing informed precision diagnostics and targeted therapies, Mbiomics aims to enhance patient outcomes and promote healthier living through innovative approaches.
hbox
Seed Round in 2023
HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.
FundaMental Pharma
Seed Round in 2022
FundaMental Pharma is a neuroscience company focused on developing innovative treatments for neurological diseases at the preclinical stage. The company creates neuroprotective molecular spacers aimed at preventing neurodegeneration in the brain. Utilizing peptides and gene therapy, FundaMental Pharma specializes in diagnosing polymorphisms and is dedicated to developing a novel class of drugs that target untreatable neurological conditions. Through its research, the company seeks to provide pharmacological solutions for patients suffering from various challenging neurological disorders.
Neotiv
Seed Round in 2022
Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.
Resolve BioSciences
Series B in 2022
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's technology offers a comprehensive, high-resolution view of subcellular gene expression activities, which is crucial for advancements in various fields such as oncology, neuroscience, and infectious diseases. Resolve BioSciences provides a range of services and expertise in bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among other areas. This innovative approach supports researchers in their efforts to explore complex biological systems and improve outcomes in health and agriculture.
IRUBIS
Seed Round in 2022
IRUBIS GmbH, founded in 2017 and based in Munich, Germany, specializes in the development of mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company focuses on enhancing Fourier transform infrared (FTIR) spectroscopy to improve the analysis of protein-based drugs. Its innovative measurement systems enable real-time bioreactor monitoring, allowing for the online assessment of glucose and lactate levels without contamination risks. IRUBIS also produces a range of ATR crystals, including single-reflection and signal-enhanced varieties, aimed at advancing industry standards for bioprocess monitoring. The company’s technology supports both upstream and downstream bioprocessing, facilitating metabolite monitoring and the detection of target proteins and contaminants through machine-learning evaluation software.
KUPANDO
Series A in 2022
Kupando is a biopharmaceutical company focused on developing TLR 4/7 agonists to enhance innate immunity. The company aims to provide cancer patients with safe and affordable immunotherapy while also creating immunostimulatory drugs to prevent infectious diseases. By targeting toll-like receptors that detect cancer and infection markers, Kupando’s therapies activate the innate immune system, allowing healthcare providers to effectively treat both cancer and infectious diseases.
Aignostics
Series A in 2022
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
FaCellitate
Seed Round in 2022
faCellitate develops polymeric platforms that aim at supporting cancer and stem cell research, drug discovery, toxicology, and tissue engineering. The platform facilitates cellular interaction, significantly improving cell culture in biological research.
Kranus Health
Series A in 2022
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Noscendo
Venture Round in 2022
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.
Tubulis
Series B in 2022
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Ceregate
Series A in 2022
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company specializes in developing a computer-brain interface (CBI) technology designed to enhance medical treatments by facilitating the direct transmission of information to neural circuits through existing neuromodulation implants. This innovative platform aims to improve the programming of neuromodulation systems, offering novel therapeutic options for patients with neurological disorders or sensory deficits. By enabling new forms of communication and sensory substitution, CereGate's technology provides patients with opportunities to adapt and improve their conditions, fostering greater independence and quality of life.
Newsenselab (M-sense)
Seed Round in 2021
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Emergence Therapeutics
Series A in 2021
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.
Nebula Biocides
Seed Round in 2021
Nebula Biocides develops application-oriented disinfection solutions that kill persistent bacterial spores and viruses.
Abalos Therapeutics
Series A in 2021
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.
Qnami
Series A in 2021
Qnami AG is a Swiss company established in 2017, specializing in the development of quantum sensing technologies for nanoscale imaging. The company manufactures non-invasive sensors, including the ProteusQ magnetic imaging microscope and the Quantum Diamond product line, which features diamond probes with single nitrogen-vacancy (NV) centers for high-resolution magnetic imaging. These advanced technologies enable the measurement of electric and magnetic fields with exceptional sensitivity, facilitating a range of applications such as the characterization of magnetic random-access memory (MRAM), imaging of proteins, and fundamental studies of superconductors. Qnami's innovations unlock new possibilities in both scientific research and industrial applications, aiming to enhance understanding and improve various aspects of life and technology.
PreComb
Seed Round in 2021
PreComb develops technologies to optimally adapt the therapies to each patient for difficult to treat cancers to increase the success rates in cancer therapy. Only an efficient use of healthcare resources can lead to a maximum improvement in the quality of life of patients.
GeneQuine Biotherapeutics
Series A in 2021
GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse.
Kranus Health
Seed Round in 2021
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Resolve BioSciences
Series A in 2020
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's technology offers a comprehensive, high-resolution view of subcellular gene expression activities, which is crucial for advancements in various fields such as oncology, neuroscience, and infectious diseases. Resolve BioSciences provides a range of services and expertise in bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among other areas. This innovative approach supports researchers in their efforts to explore complex biological systems and improve outcomes in health and agriculture.
Synendos Therapeutics
Series A in 2020
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.
Aignostics
Seed Round in 2020
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
stimOS
Series A in 2020
stimOS GmbH, founded in 2015 and based in Constance, Germany, specializes in the development of innovative drug delivery systems that promote bone formation, anti-inflammatory responses, and healing processes. The company creates advanced technologies to refine, functionalize, and activate implant materials, transforming them into interfaces that closely mimic natural bone. By offering these technologies to implant manufacturers, stimOS supports the production of implants that enhance patient recovery and facilitate a pain-free post-surgical experience. Through its focus on research and development, stimOS aims to advance the field of implant technology and improve patient outcomes.
Tubulis
Series A in 2020
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
NovaPump
Series A in 2020
The NovaPump GmbH is a cardiology company based in Jena/Germany devoloping cutting-edge therapeutical solutions in the field of non-invasive and percutaneous circulation support. The so called PERKAT (PERKutane KATheterpumpe) technique will be offered as pLVAD & pRVAD heart pumps for acute left or right heart patients within the next years. PERKAT works together with the current IABP technique (intra aortic balloon pump with about 200,000 cases p.a. internationally) and is the only-one catheter-based & self-expanding, pulsatile & ECG-triggered, cost-effective heart pump technique with a high pump performance. PERKAT is not available on the market so far. Articles in leading scientific journals and presentations at the top four international cardiology conferences in the last years show the medical need, the development status and the technological and medical advantages of PERKAT.
Kumovis
Series A in 2020
Kumovis is a medical technology company focused on advancing the field of 3D printing for industrial and medical applications. It has developed a specialized 3D printing system that integrates clean room technology, allowing for the precise processing of high-performance polymers. This innovation enables the creation of patient-customized implants, facilitating more convenient and effective medical operations in hospitals. Through its cutting-edge technology, Kumovis aims to enhance the capabilities of medical professionals and improve patient outcomes.
Noscendo
Series A in 2020
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, specializing in bioinformatics solutions for the identification and assessment of pathogens associated with bloodstream infections. The company utilizes Next Generation Sequencing (NGS) to enable intensive care clinicians to detect bacteria, fungi, viruses, and parasites from a single standard blood draw, without the need for prior cultivation or detailed knowledge of the infection's nature. Its proprietary algorithms assess the relevance of each identified pathogen, allowing for precise differentiation between commensals, contamination, and actual infection. Noscendo's innovative platform aims to enhance the efficiency and accuracy of pathogen detection in clinical settings.
Scipio Bioscience
Series A in 2020
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.
Ceregate
Venture Round in 2020
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company specializes in developing a computer-brain interface (CBI) technology designed to enhance medical treatments by facilitating the direct transmission of information to neural circuits through existing neuromodulation implants. This innovative platform aims to improve the programming of neuromodulation systems, offering novel therapeutic options for patients with neurological disorders or sensory deficits. By enabling new forms of communication and sensory substitution, CereGate's technology provides patients with opportunities to adapt and improve their conditions, fostering greater independence and quality of life.
HepaRegenix
Series B in 2020
HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.
Mecuris
Series B in 2020
Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.
Newsenselab (M-sense)
Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Verovaccines
Seed Round in 2019
VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target animal species against different viral diseases (proof-of-concept). VEROVACCiNES GmbH is a spin-off company of the Martin Luther University Halle-Wittenberg, Germany in 2017. The company exclusively took over IP, brand, team, products and know-how from the former BMBF GO-Bio-funded VEROVACCiNES project at Halle University. VEROVACCiNES GmbH is eligible for follow-up phase 2 funding from the same BMBF GO-Bio program. They cooperate closely with veterinary pharmaceutical companies, universities and research institutes, and they are eager to initiate new collaborations.
Qnami
Seed Round in 2019
Qnami AG is a Swiss company established in 2017, specializing in the development of quantum sensing technologies for nanoscale imaging. The company manufactures non-invasive sensors, including the ProteusQ magnetic imaging microscope and the Quantum Diamond product line, which features diamond probes with single nitrogen-vacancy (NV) centers for high-resolution magnetic imaging. These advanced technologies enable the measurement of electric and magnetic fields with exceptional sensitivity, facilitating a range of applications such as the characterization of magnetic random-access memory (MRAM), imaging of proteins, and fundamental studies of superconductors. Qnami's innovations unlock new possibilities in both scientific research and industrial applications, aiming to enhance understanding and improve various aspects of life and technology.
Abalos Therapeutics
Series A in 2019
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.
Vacis
Venture Round in 2019
Vacis is a leading tissue engineering company focused on developing innovative solutions for vascular surgery. The company specializes in creating in situ tissue-engineered blood vessels, addressing a significant challenge in the field: the frequent failure of prosthetic vascular grafts, which often leads to complications and increased healthcare costs. Vacis's technology employs a synthetic rod with a specialized surface, which, when inserted under the skin, stimulates the body to form a tissue capsule that matures into a functional blood vessel. This process allows for the creation of autologous graft vessels that offer sustained patency and reduce the need for corrective interventions, ultimately providing patients with safer and more effective options for vascular access, particularly in hemodialysis.
Tacalyx
Seed Round in 2019
Tacalyx GmbH is an oncology company based in Berlin, Germany, specializing in the discovery and development of Tumor-Associated Carbohydrate Antigens (TACAs) as innovative targets for cancer therapy. Originating as a spin-off from the Max-Planck-Institute of Colloids and Interfaces, Tacalyx leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures are essential for generating and identifying antibodies aimed at developing new therapeutics. TACAs are characterized by their specific expression in tumors, which arises from abnormal glycosylation and is associated with promoting metastasis, angiogenesis, and immune system suppression. By combining sophisticated synthesis capabilities with comprehensive analysis and screening, Tacalyx aims to create novel immunotherapies that effectively stimulate anti-cancer responses.
Belyntic
Seed Round in 2019
Belyntic is a biotechnology company focused on developing innovative vaccines aimed at addressing viral diseases, bacterial infections, and cancer. The company has created a novel platform technology that produces self-adjuvant synthetic long peptides, which promote safe and durable cellular immunity. Belyntic offers ready-to-use research kits and engineered vaccines designed to activate T-cell immune responses, providing significant potential for the advancement of protective vaccines. Additionally, the company integrates artificial intelligence to predict pathogen-specific epitopes, enhancing the design of its self-adjuvant nano vaccine structures. This approach supports clients in the research, development, and production of novel peptide therapeutics, contributing to improved health outcomes.
miRdetect
Seed Round in 2019
miRdetect GmbH is a Bremen-based company that specializes in the development and marketing of in-vitro diagnostics for cancer detection. Founded in 2016, the company offers products such as miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect focuses on creating and manufacturing molecular biological tests that enable the early identification and diagnosis of various cancers by accurately detecting minute quantities of nucleic acids. In addition to its existing products, the company is actively engaged in research and development to expand its portfolio of diagnostic tests.
Cytena
Series A in 2019
Cytena GmbH is a biotechnology company based in Freiburg, Germany, specializing in the development of laboratory devices for the separation and printing of single cells. Founded in 2014, the company offers innovative products such as the cy-Clone and a range of single-cell printing technologies, which are essential for applications in drug development and genetic analysis, particularly in cancer and stem cell research. The cy-Clone utilizes an automated imaging process to encapsulate single cells in droplets, ensuring their viability and preventing cross-contamination through the use of disposable components. Cytena's technology enables efficient and contact-free deposition of cells on various substrates, facilitating the analysis and growth of clonal colonies. With a distribution network that spans Europe, North America, India, Asia, and the United Kingdom, Cytena operates as a subsidiary of Cellink AB, enhancing the capabilities of researchers and developers in the life sciences sector.
Plasmion
Seed Round in 2019
The only "chemoselective" sense of human kind is the sense of smell. Through this sense They are able to perceive taste, aroma, and hazardous substances, such as hydrogen sulfide. Unfortunately, this sense is evolutionarily hampered for human beings compared to animals like dogs, for instance. Also from a technological perspective there is no sensitive and selective "electronic nose" available, yet. Therefore, thay are strive to provide a novel sensor technology based on ambient mass spectrometry which does not only improve the utilization in traditional laboratory environments, but also enables the transfer of this kind of sensor technology to industrial process control, forensics, security technology (drugs, explosives, etc.) and the medical "point of care" diagnostics.
Mecuris
Series A in 2019
Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.
PreOmics
Series A in 2018
PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.
denovoMATRIX
Seed Round in 2018
denovoMATRIX GmbH specializes in the development and production of biomimetic coatings for stem cell culture, aiming to enhance cell manufacturing quality, quantity, and safety. Founded in 2018 and based in Dresden, Germany, the company offers products such as screenMATRIX, which facilitates various cellular functions including adhesion, differentiation, and organization, and myMATRIX, a custom-coated tissue cultureware designed for the growth of stem cells and primary cells in serum-free media. These innovative biomaterials are utilized in stem cell research, tissue modeling, and cell-based therapies, providing researchers with tailored solutions to address specific scientific inquiries and potential medical applications.
Amal Therapeutics
Series B in 2018
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
OMEICOS Therapeutics
Series C in 2018
OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.
Kumovis
Seed Round in 2018
Kumovis is a medical technology company focused on advancing the field of 3D printing for industrial and medical applications. It has developed a specialized 3D printing system that integrates clean room technology, allowing for the precise processing of high-performance polymers. This innovation enables the creation of patient-customized implants, facilitating more convenient and effective medical operations in hospitals. Through its cutting-edge technology, Kumovis aims to enhance the capabilities of medical professionals and improve patient outcomes.
Adivo
Seed Round in 2018
adivo is a veterinary biotechnology company developing therapeutic antibodies for pets. The focus is on the treatment of serious diseases in dogs with the potential to offer therapies for other species as well. The antibody selection is based on a new, fully synthetic, dog-specific drug library that can be used to isolate antibodies with optimal properties using phage display technology. adivo is a spin-off of MorphoSys AG. Many years of expertise in the development of human therapeutic antibodies transfer the adivo team into veterinary medicine.
advanceCOR
Venture Round in 2018
advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases. Its products include Revacept, a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury; COR-2, a recombinant protein that interferes with the generation of foam cells; and COR-3, a recombinant protein, which specifically binds to atherosclerotic plaques, and then bi-specifically binds to circulating progenitor cells to trap the endogenously occurring progenitor cells for accelerated plaque healing.
Neotiv
Seed Round in 2018
Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.
heartbeat medical
Venture Round in 2017
Heartbeat enables providers to learn from the most important data point in healthcare: quality of life. We are experts in the field of Patient Reported Outcome Measures (PROMs) and passionate about generating high-quality Real World Evidence.
RIMASYS
Venture Round in 2017
RIMASYS is the novel approach to surgical education and MedTech R&D. They enable medical science, academia, and the industry to develop better implants, and perform more advanced therapies, operations - with the aim to increase the quality of life for patients. RIMASYS is focusing on enhancing surgical education and improving patient outcomes by deploying realistic fractures for practical skill training and medical device development.
Amal Therapeutics
Series B in 2017
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
stimOS
Seed Round in 2017
stimOS GmbH, founded in 2015 and based in Constance, Germany, specializes in the development of innovative drug delivery systems that promote bone formation, anti-inflammatory responses, and healing processes. The company creates advanced technologies to refine, functionalize, and activate implant materials, transforming them into interfaces that closely mimic natural bone. By offering these technologies to implant manufacturers, stimOS supports the production of implants that enhance patient recovery and facilitate a pain-free post-surgical experience. Through its focus on research and development, stimOS aims to advance the field of implant technology and improve patient outcomes.
SciRhom
Seed Round in 2017
SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academic and industry scientists with profound experience in antibody development.
HepaRegenix
Series A in 2016
HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.
AudioCure Pharma
Series A in 2016
AudioCure Pharma GmbH is a pharmaceutical company based in Berlin, Germany, focused on developing treatments for hearing impairments and neurodegenerative diseases. Founded in 2012 by Professor Hans Rommelspacher, a clinician and academic, the company is supported by a team of skilled scientists and executives, alongside a network of academic partners and strategic investors. AudioCure’s operations are strategically located in Mitte, providing access to Berlin's vibrant tech and academic scene, including close ties with Charité University, which facilitates collaboration with leading experts. The company is advancing its lead compound, AC102, which is in late-stage preclinical development for acute noise-induced hearing loss, having achieved preclinical proof of concept in 2016.
Newsenselab (M-sense)
Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Mecuris
Seed Round in 2016
Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.
Immunic Therapeutics
Series A in 2016
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company has a pipeline that includes three small molecule products. Its lead program, IMU-838, is a selective immune modulator that works by inhibiting the enzyme DHODH, targeting conditions such as multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. The second product, IMU-935, functions as an inverse agonist of the transcription factor RORγt and is being developed for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Lastly, IMU-856 aims to restore intestinal barrier function and is intended for diseases associated with bowel barrier dysfunction. Through these innovative therapies, Immunic Therapeutics aims to address significant unmet medical needs in the field of immunology.
CryoTherapeutics
Series B in 2016
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
bentekk
Seed Round in 2016
Bentekk GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development and manufacture of intelligent gas measuring systems aimed at on-site analysis of contaminants. The company produces portable gas measurement devices that utilize gas chromatography and photo ionization detection for the assessment of volatile organic compounds, including hazardous substances like benzene. These devices are designed to enhance occupational health and safety across various sectors, including environmental monitoring, emergency response, logistics, life sciences, and the chemical industry. By providing accurate and rapid measurements of toxic gases, Bentekk supports improved safety and compliance with threshold limit values, contributing to a safer working environment. As of April 2017, Bentekk operates as a subsidiary of Dräger Safety AG & Co. KGaA.
Amal Therapeutics
Series A in 2016
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
SeNostic Health GmbH
Seed Round in 2016
We develop innovative in vitro diagnostic tests for neurodegenerative disorders.
Abviris Deutschland
Seed Round in 2016
Whilst alcohol abuse and smoking as risk factors for oral cancer are rather easy to obtain, HPV infections typically don´t show any early symptoms. Nowadays, suspect lesions are usually detected in very late stages of cancerogenesis. The oral cavity offers numerous hidden spots, which are typically not inspected during a routine visit in the dental surgery.
heartbeat medical
Venture Round in 2016
Heartbeat enables providers to learn from the most important data point in healthcare: quality of life. We are experts in the field of Patient Reported Outcome Measures (PROMs) and passionate about generating high-quality Real World Evidence.
LifeTime
Seed Round in 2016
LifeTime is a digital health application developed by connected-health.eu GmbH since 2014, which has established itself as a leading and secure solution for the digital management and transmission of medical data. The application facilitates the efficient and accurate exchange of medical documents, including findings and images, between healthcare professionals and patients. By enabling secure digital communication, LifeTime enhances the clarity of health and treatment histories for users, streamlining workflows for doctors and medical staff. In 2019, LifeTime GmbH acquired the platform, signaling a new phase of development and enhancement under its management.
Venneos
Seed Round in 2015
Venneos GmbH is a German high-tech startup based in Stuttgart. Founded in 2014 as a spin-off from Max Planck Society, it develops and markets the ‘CAN-Q‘, a silicon-chip-based imaging system for the label-free analysis of biological cells. Venneos’ products build upon the innovative technology ‘CAN-Spectroscopy’ that allows customers to detect cellular changes for example in the area of cell adhesion which remain invisible with other technologies.undation of modern computers and approximately 80% of all new technologies are based on it.
Eyetronic Therapie
Venture Round in 2015
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.
Cytena
Seed Round in 2015
Cytena GmbH is a biotechnology company based in Freiburg, Germany, specializing in the development of laboratory devices for the separation and printing of single cells. Founded in 2014, the company offers innovative products such as the cy-Clone and a range of single-cell printing technologies, which are essential for applications in drug development and genetic analysis, particularly in cancer and stem cell research. The cy-Clone utilizes an automated imaging process to encapsulate single cells in droplets, ensuring their viability and preventing cross-contamination through the use of disposable components. Cytena's technology enables efficient and contact-free deposition of cells on various substrates, facilitating the analysis and growth of clonal colonies. With a distribution network that spans Europe, North America, India, Asia, and the United Kingdom, Cytena operates as a subsidiary of Cellink AB, enhancing the capabilities of researchers and developers in the life sciences sector.
OMEICOS Therapeutics
Series A in 2015
OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.
Sonormed GmbH
Series A in 2015
Sonormed GmbH is a medical technology company focusing on digital audiology.
4 Animals AlsterScience GmbH
Venture Round in 2014
4 Animals AlsterScience GmbH is a Hamburg, Germany-based developer of biologic drugs and feed supplements for animals that improve immune function. The company’s products have already been used for viral diseases, tumors, inoculations and cell therapies and can help break the vicious cycle of resistance to conventional drugs.
Medineering
Seed Round in 2014
Medineering is a medical technology company based in Munich, Germany, specializing in innovative robotic systems for minimally invasive head surgery. Founded in 2014, the company develops, patents, and sells a modular range of surgical manipulators that enable clinics and surgeons to customize the level of automation and functionality based on their specific surgical needs and budget constraints. Its product portfolio includes an intelligent positioning arm and compact, application-specific robots designed to assist surgeons in navigating complex anatomical regions. Medineering aims to enhance the potential of minimally invasive surgery through advanced robotic solutions that optimize surgical access and improve working conditions in the operating room.
i3 Membrane
Seed Round in 2014
i3 Membrane GmbH, established in 2013 and based in Dresden, Germany, specializes in the manufacture of steel filter membranes tailored for the life sciences sector, including medical and pharmaceutical applications. The company focuses on developing innovative separation technologies that utilize ion and membrane technology, resulting in membranes that are temperature-resistant, flexible, and durable. These membranes are designed for various applications such as sample preparation, virus concentration, and protein separation or removal. i3 Membrane aims to provide advanced solutions that enhance efficiency in separation processes, addressing both current and future challenges within research, development, and production in the life sciences field.
microDimensions
Seed Round in 2014
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products that can be integrated into the existing customer workflow seamlessly.
Coramaze Technologies
Seed Round in 2014
Coramaze Technologies is a medical device company focused on developing innovative solutions for heart diseases. Founded in 2013 and headquartered in Munich, Germany, the company is working on a minimally invasive valve repair system aimed at treating patients with structural heart valve diseases. Their flagship product, the Mitramaze valve repair system, is a catheter-based device designed for implantation directly into the beating heart, catering to inoperable and asymptomatic patients. Additionally, Coramaze is advancing an adaptive tricuspid valve repair device known as Tripair, which is designed to be anchored in the right atrium, facilitating a quick and straightforward procedure accessible in catheterization labs. This technology aims to address functional mitral regurgitation resulting from heart enlargement due to conditions like heart attacks or heart failure, thus providing less invasive treatment options for patients who might otherwise go without proper care.
OMEICOS Therapeutics
Seed Round in 2013
OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.
Synoste
Venture Round in 2013
Synoste Oy, founded in 2007 and based in Espoo, Finland, specializes in developing innovative solutions for the treatment of skeletal deformities. The company focuses on patient-friendly technologies for various conditions, including congenital limb discrepancies, trauma-related injuries, and craniomaxillofacial deformities. Its flagship product is a third-generation limb-lengthening system that incorporates smart materials, designed to enhance patient comfort during the often-complicated lengthening procedure. This advanced device aims to reduce complications and facilitate quicker recovery, making it a significant improvement over traditional methods. As a subsidiary of Globus Medical, Inc., Synoste continues to advance its mission of providing effective and less painful treatment options for individuals with skeletal deformities.
NovaPump
Seed Round in 2013
The NovaPump GmbH is a cardiology company based in Jena/Germany devoloping cutting-edge therapeutical solutions in the field of non-invasive and percutaneous circulation support. The so called PERKAT (PERKutane KATheterpumpe) technique will be offered as pLVAD & pRVAD heart pumps for acute left or right heart patients within the next years. PERKAT works together with the current IABP technique (intra aortic balloon pump with about 200,000 cases p.a. internationally) and is the only-one catheter-based & self-expanding, pulsatile & ECG-triggered, cost-effective heart pump technique with a high pump performance. PERKAT is not available on the market so far. Articles in leading scientific journals and presentations at the top four international cardiology conferences in the last years show the medical need, the development status and the technological and medical advantages of PERKAT.
Middle Peak Medical
Series A in 2013
Middle Peak Medical is a privately held medical device company focused on the development and commercialization of a novel technology to treat mitral valve disease. The company’s proprietary device has application in both percutaneous catheter-based intervention, and in minimally invasive or open-heart cardiac surgery.
Eyetronic Therapie
Series B in 2013
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.
CardioSecur
Series A in 2013
CardioSecur, a subsidiary of Personal MedSystems, focuses on innovative mobile health solutions, particularly in the realm of instant cardiac monitoring. The company has developed a smartphone-based ECG application that includes a specialized set of electrodes for efficient data collection. This application allows users to conduct personalized cardiac monitoring and facilitates the sharing of results with healthcare providers, enabling patients to receive timely recommendations on their health status in under a minute. By prioritizing ease of use and sophisticated design, CardioSecur aims to deliver professional-grade ECG technology for individuals, enhancing personal health management.
GeneQuine Biotherapeutics
Seed Round in 2012
GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse.
JeNaCell
Seed Round in 2012
Jena Cell has a unique and patented technology for the continuous production of a high performance biomaterial with natural nanostructures.
AYOXXA
Series A in 2012
AYOXXA Biosystems GmbH is a life science tools company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in developing a proprietary technology platform for multiplexed protein analysis. This platform, which utilizes In-situ Encoded Bead-based Arrays, enables users to simultaneously measure multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's innovative biochips merge biological analysis with information technology, expanding the potential applications in biomedical research. The company also offers biomarker kits to facilitate the identification and quantification of proteins and other biomolecular analytes.
AudioCure Pharma
Seed Round in 2012
AudioCure Pharma GmbH is a pharmaceutical company based in Berlin, Germany, focused on developing treatments for hearing impairments and neurodegenerative diseases. Founded in 2012 by Professor Hans Rommelspacher, a clinician and academic, the company is supported by a team of skilled scientists and executives, alongside a network of academic partners and strategic investors. AudioCure’s operations are strategically located in Mitte, providing access to Berlin's vibrant tech and academic scene, including close ties with Charité University, which facilitates collaboration with leading experts. The company is advancing its lead compound, AC102, which is in late-stage preclinical development for acute noise-induced hearing loss, having achieved preclinical proof of concept in 2016.
Algiax Pharmaceuticals
Series A in 2012
Algiax Pharmaceuticals GmbH is a biotechnology company based in Erkrath, Germany, founded in April 2011. The company specializes in the discovery and development of innovative products aimed at treating nervous system diseases and dysfunctions, with a particular emphasis on neuropathic pain and spinal cord injuries. Algiax Pharmaceuticals develops molecules that inhibit the enzyme dehydroorotate dehydrogenase, addressing central nervous system disorders associated with chronic pain. The company has demonstrated financial stability, having raised 4.3 million Euros in Series A financing from a consortium of private and state-backed investors. Algiax Pharmaceuticals is committed to addressing significant unmet medical needs in the field of neurology.
t-cell Europe GmbH
Seed Round in 2012
t-cell Europe is a medical company that develops T-cell-based therapies based on IP-protected platform technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.